Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25543839 | 0.80 | CYP1A2 (0.47) | IDO1METAP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3424160 | 0.78 | IDO1 (0.55) | IDO1METAP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26301694 | 0.77 | TGFBR1 (0.49) | CYP1A2LDHANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30480541 | 0.76 | LDHA (0.56) | IDO1ALDH1A1LDHANPC1RAB9A | |
| SCHEMBL13299607 | 0.76 | LDHA (0.56) | IDO1ALDH1A1LDHANPC1RAB9A | |
| SCHEMBL13680761 | 0.76 | ACHE (0.44) | IDO1METAP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16716059 | 0.76 | CYP1A2 (0.51) | IDO1METAP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8227859 | 0.76 | CCR1 (0.60) | IDO1METAP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16526672 | 0.76 | IDO1 (0.44) | IDO1METAP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL30229669 | 0.74 | NPC1 (0.59) | IDO1METAP2CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051179-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8791095-B2 | Steroidal CYP17 inhibitors/antiandrogens | TOKAI PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20100222547-A1 | Integrated Photoactive Peptides and Uses Thereof | MALLINCKRODT INC. | 2010-09-02 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | IDO1 1467/4885METAP2 4175/4885CYP1A2 42/4885 |
| US-20100222547-A1 | Integrated Photoactive Peptides and Uses Thereof | DNPEP, PTMS, VIP | IDO1 423/4885METAP2 32/4885CYP1A2 3506/4885 |
| US-20150051179-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | IDO1 1467/4885METAP2 4175/4885CYP1A2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.